CFA Level I · Cheat Sheet
Cue: Assess industry profitability and competitive intensity
| Force | High = Bad For Profitability | Low = Good For Profitability | ||
| Threat of New Entrants | Low barriers to entry | High barriers (scale, patents, capital, brand, switching costs) | ||
|---|---|---|---|---|
| Supplier Power | Few suppliers, can raise prices | Many suppliers, fragmented | ||
| Buyer Power | Few large buyers, price sensitive | Fragmented buyers, low price sensitivity | ||
| Threat of Substitutes | Good substitutes available | Few/no substitutes | ||
| Competitive Rivalry | Many competitors, commoditized products | Few competitors, differentiated products | ||
| Stage | Growth | Competition | Margins | Valuation Approach |
| Embryonic | Slow, market developing | Few players, high failure risk | Low/negative | High growth assumptions, high risk |
| Growth | Rapid expansion | Increasing competitors attracted | Expanding | Higher multiples, reinvestment needs |
| Shakeout | Slowing growth | Intense, weaker players exit | Pressure | Risky; survivors have durable moats |
| Mature | Slow, stable (GDP-like) | Consolidated, stable rivalry | Stable | Modest multiples, focus on efficiency |
| Decline | Negative | Consolidation or exit | Compressed | Low multiples; terminal value near zero |
| Source | Definition | Example | Durability | |
| Cost Advantages | Scale economies, proprietary tech, low-cost inputs | Intel chip manufacturing, Walmart sourcing | Medium-High | |
| Intangible Assets | Patents, brands, licenses, regulatory approval | Pharma patents, branded pharmaceuticals | High if renewed/protected | |
| Switching Costs | Customer lock-in (embedded software, loyalty) | Enterprise software, payment networks | High | |
| Network Effects | Value increases with # users (two-sided markets) | Visa/Mastercard, LinkedIn, Uber | Very High | |
| Efficient Scale | Natural monopoly in limited market | Regional utility, local telecom | High if uncontested | |
| Assumption | Typical Range | Risk | ||
| Terminal growth rate (g) | 2–3% GDP-like for mature | Overly optimistic g → inflates value | ||
| WACC | 6–10% depending on risk | WACC changes dominate TV | ||
| Type | Weight by | Bias | Maintenance | |
| Price-Weighted | Stock price per share | Favors high-priced stocks (unrelated to size); stock splits distort | Infrequent rebalancing | |
| Market-Cap-Weighted | Market capitalization | Momentum bias (winners get heavier); concentration risk | Passive drift | |
| Float-Adjusted | Tradeable shares only | More representative; excludes insider/gov blocks | Passive drift | |
| Equal-Weighted | Same weight all constituents | Value tilt (rebalancing sells winners, buys losers) | Frequent rebalancing | |
| Concept A | Concept B | Key Difference | ||
| Switching Costs | Network Effects | Switching: I'm locked in because leaving is painful. Network: System becomes more valuable as more users join. | ||
| Barriers to Entry | Competitive Advantage Period | Entry barriers: Why new competitors can't easily enter. CAP: How long incumbent can earn excess returns. | ||
| Price-Weighted Index | Equal-Weighted Index | Price: High-priced stock dominates (unrelated to size). Equal: All stocks same weight; requires active rebalancing. | ||
| Mature Stage | Declining Stage | Mature: Stable slow growth, consolidated structure. Declining: Negative growth, disruption or demand loss. |
✓ Patent cliff = pharmaceutical CAP terminus; triggers dramatic margin collapse ✓ Two-sided network effects (e.g., Visa
Aligned to the CFA Institute Level I curriculum.
Personalize this sheet — focus it however you study, or build one from the exact questions you keep getting wrong.